NCT00193063View on ClinicalTrials.gov

Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

May 31, 2009

Study Completion Date

August 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

Trastuzumab

DRUG

Gemcitabine

Gemcitabine

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER